Stay updated with breaking news from Michaelc Wu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Data from a national clinical trial shows that a striking 89% of patients with desmoplastic melanoma responded to immunotherapy (pembrolizumab) alone, suggesting that many patients could avoid the risk for toxicity from combination therapies and achieve cancer control with this approach to treatment.
Close to 90 percent of patients with unresectable (inoperable) desmoplastic melanoma, a rare form of skin cancer, saw their cancer improve after treatment with the immunotherapy drug pembrolizumab in a recent clinical trial. These results from the S1512 trial are being delivered in an oral presentation at the clinical trials plenary session of the 2023 annual meeting of the American Association for Cancer Research (AACR) in Orlando, Florida, on April 16th.
Transactions are happening fast even on the highest-priced homes in the region.